Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients

AIDS. 2014 Sep 10;28(14):2157-9. doi: 10.1097/QAD.0000000000000374.

Abstract

Previous in-vitro data pointed out lithium, an activator of the β-catenin signalling pathway, as a modulator of HIV-1 transcription. We assessed the effect of in-vivo administration of lithium on viral latency modulation in nine antiretroviral therapy (ART)-suppressed HIV-1-infected individuals. We found that lithium carbonate treatment was able to transiently repress HIV-1 residual expression in CD4 T cells in vivo, which led to a concomitant short-term decrease in the proviral reservoir size.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • DNA, Viral
  • HIV Infections / drug therapy*
  • HIV Infections / genetics
  • HIV Infections / immunology
  • HIV-1* / genetics
  • Humans
  • Linolenic Acids / pharmacology*
  • Lithium Compounds / pharmacology*
  • Proviruses* / genetics
  • Signal Transduction
  • Viral Load / drug effects*
  • Virus Latency / drug effects
  • Virus Latency / immunology
  • Virus Replication
  • beta Catenin / genetics
  • beta Catenin / immunology

Substances

  • Anti-HIV Agents
  • DNA, Viral
  • Linolenic Acids
  • Lithium Compounds
  • beta Catenin